o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine transglycosylase (TGT) enzyme pathway against a range of autoimmune diseases without interfering with the body’s immune system.
As part of the kickstarter programme, o2h discovery will be providing small molecule synthetic chemistry to deliver improved medicines for patients with autoimmune disease, including Multiple Sclerosis.